What is it?
The purpose of the CSHP OB Journal Club is to foster evidence-based, timely and contextualized learning that has immediate or near-future implications on front-line practice. Journal Club is structured as a 30-minute facilitated discussion over teleconference occurring on the last Thursday of each month (except December and January) from 1200-1230h.
Papers are disseminated by email 2-3 weeks in advance with accompanying backgrounder articles to enhance understanding of the topic where appropriate. Participation is open to all CSHP members and is completely voluntary. Some pharmacists may prefer to read the articles on their own, while others may call in more or less regularly if they prefer to have a discussion or learn how other hospitals and pharmacists are approaching a particular clinical problem. The overall atmosphere is informal and conversational as we learn clinical pearls from each other and share common wins and challenges in our own practices.
Papers are not limited to randomized controlled trials. Systematic reviews, narrative reviews, meta-analyses, cohort/case control studies, clinical guidelines, teachable moments, commentaries on clinical practice, ISMP Canada Safety Bulletins, CJHP point/counterpoint articles and Health Canada's Health Product InfoWatch publications will also be chosen based on their applicability to clinical practice. CSHP members are always encouraged to suggest topics and/or articles for future journal club sessions.
Upcoming Journal Club:
Topic: Anti-phospholipid Syndrome (APS) 101 for the Clinical Pharmacist
|Date: Thursday, November 28th, 2019|
|Time: 12-12:30 PM EST|
APS is an acquired hypercoagulable state caused by antibodies against cell membrane phospholipids. While it is not curable, it can be managed with anti-coagulants. Mainstay treatment has been warfarin and LWMH during high risk periods. The role of DOACs in antiphospholipid antibody syndrome (APS) remains uncertain.
Join us on November 28th for a review of APS including pathophysiology, diagnosis, treatment options and supporting evidence or lack thereof for DOACs.
Relevant to pharmacists working in ambulatory care and all acute care areas. Sharing of clinical experiences is highly encouraged for this session.
2019 Journal Clubs
Primary article: Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics
SLGT2 inhibitors – Are they the new class in heart failure?
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthoplasty (EPCAT2)